AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic470
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology46
  • Immunology176
  • Infectious Disease146
  • Nephrology130
  • Neurology478
  • Oncology1,193
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases142
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic470
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology46
  • Immunology176
  • Infectious Disease146
  • Nephrology130
  • Neurology478
  • Oncology1,193
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases142
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

What's new

Changes applied to the site, newest first.

What's new

  1. 3 hours ago
    Filing Immix Biopharma, Inc.: Results of operations and financial condition ↗
    Immix Biopharma, Inc.
  2. 3 hours ago
    Drug Added to the terminal: Sovleplenib
  3. 3 hours ago
    Drug Added to the terminal: Fanregratinib
  4. 19 hours ago
    Readout Primary readout date moved: Iparomlimab (QL1604)
    2026-10-31 → 2027-10-31
  5. 19 hours ago
    Readout Primary readout date moved: Iparomlimab and tuvonralimab
    2026-10-31 → 2027-10-31
  6. 19 hours ago
    Readout Primary readout date moved: Oxycodone (Xtampza ER)
    2026-12 → 2027-09
  7. 19 hours ago
    Trial Trial status changed: Tamoxifen (Soltamox)
    Not yet recruiting → Withdrawn
  8. 19 hours ago
    Trial Trial status changed: IncobotulinumtoxinA (Xeomin)
    Recruiting → Completed
  9. 19 hours ago
    Trial New registered study: Clesrovimab
    4 · NOT_YET_RECRUITING
  10. 19 hours ago
    Trial New registered study: buprenorphine extended-release
    2 · NOT_YET_RECRUITING
  11. 19 hours ago
    Trial New registered study: Tirzepatide (Zepbound)
    4 · RECRUITING
  12. 22 hours ago
    News Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy ↗
    Capricor Therapeutics
  13. 1 day ago
    Filing Senti Biosciences: Change of certifying accountant ↗
    Senti Biosciences
  14. 1 day ago
    News Abivax Statement on Short Seller Report ↗
    Abivax
  15. 1 day ago
    News Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement ↗
    Avenzo Therapeutics, Inc.
  16. 1 day ago
    News Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference ↗
    Teva Pharmaceutical Industries
  17. 2 days ago
    Insider Form 4 filed: Annexon, Inc.
  18. 2 days ago
    Insider Form 4 filed: Ardelyx
  19. 3 days ago
    Earnings Earnings date sourced: Alpha Compute Corp
    2027-01-11
  20. 6 days ago
    Financials New financial period: Kiora Pharmaceuticals, Inc.
    2026-Q3
  21. 6 days ago
    Financials New financial period: XBiotech
    2026-Q3
  22. 11 days ago
    Earnings Earnings date sourced: Pfizer
    2027-02-02